» Articles » PMID: 37061693

EXCHANGE-2: Investigating the Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic Shock-a Study Protocol for a Randomized, Prospective, Multicenter, Open-label, Controlled, Parallel-group Trial

Overview
Journal Trials
Publisher Biomed Central
Date 2023 Apr 15
PMID 37061693
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Sepsis is as a life-threatening organ dysfunction caused by a dysregulated host response to an infection. The mortality of sepsis and particular of septic shock is very high. Treatment mostly focuses on infection control but a specific intervention that targets the underlying pathological host response is lacking to the present time. The investigators hypothesize that early therapeutic plasma exchange (TPE) will dampen the maladaptive host response by removing injurious mediators thereby limiting organ dysfunction and improving survival in patients with septic shock. Although small prospective studies demonstrated rapid hemodynamic stabilization under TPE, no adequately powered randomized clinical trial has investigated hard outcomes.

Methods: This is a randomized, prospective, multicenter, open-label, controlled, parallel-group interventional trial to test the adjunctive effect of TPE in patients with early septic shock. Patients with a refractory (defined as norepinephrine (NE) ≥ 0.4 μg/kg/min ≥ 30 min OR NE 0.3 μg/kg/min + vasopressin) and early (shock onset < 24 h) septic shock will be included. The intervention is a standard TPE with donor fresh frozen plasma (1.2 × individual plasma volume) performed within 6 h after randomization and will be compared to a standard of care (SOC) control arm. The primary endpoint is 28 days mortality for which the power analysis revealed a group size of 137 / arm (n = 274) to demonstrate a benefit of 15%. The key secondary objective will be to compare the extent of organ failure indicated by mean SOFA over the first 7 days as well as organ support-free days until day 28 following randomization. Besides numerous biological secondary, safety endpoints such as incidence of bleeding, allergic reactions, transfusion associated lung injury, severe thrombocytopenia, and other severe adverse events will be assessed during the first 7 days. For exploratory scientific analyses, biomaterial will be acquired longitudinally and multiple predefined scientific subprojects are planned. This study is an investigator-initiated trial supported by the German Research Foundation (DFG, DA 1209/7-1), in which 26 different centers in Germany, Switzerland, and Austria will participate over a duration of 33 months.

Discussion: This trial has substantial clinical relevance as it evaluates a promising adjunctive treatment option in refractory septic shock patients suffering from an extraordinary high mortality. A positive trial result could change the current standard of care for this septic subgroup. The results of this study will be disseminated through presentations at international congresses, workshops, and peer-reviewed publications.

Trial Registration: ClinicalTrials.gov NCT05726825 , Registered on 14 February 2023.

Citing Articles

A few words of caution on blood purification in sepsis.

Stahl K, Wendel-Garcia P, Bode C, David S Crit Care. 2025; 29(1):45.

PMID: 39856722 PMC: 11762067. DOI: 10.1186/s13054-025-05268-z.


Effect of therapeutic plasma exchange on tissue factor and tissue factor pathway inhibitor in septic shock.

Stahl K, Lehner G, Wendel-Garcia P, Seeliger B, Pape T, Schmidt B Crit Care. 2024; 28(1):351.

PMID: 39478586 PMC: 11526504. DOI: 10.1186/s13054-024-05142-4.


[Extracorporeal procedures in sepsis].

Bernard A, Koeppen M Anaesthesiologie. 2024; 73(10):713-720.

PMID: 39331071 DOI: 10.1007/s00101-024-01464-8.


[What is confirmed in the treatment of sepsis? : An update].

Hillebrand U, Rex N, Seeliger B, Stahl K, Schenk H Inn Med (Heidelb). 2024; 65(12):1199-1208.

PMID: 39320478 DOI: 10.1007/s00108-024-01794-0.


Enhancing Survival in Septic Shock: A Systematic Review and Meta-Analysis of the Efficacy of Plasma Exchange Therapy.

Hernandez G, Francis A, Hamid P Cureus. 2024; 16(5):e60947.

PMID: 38910774 PMC: 11193551. DOI: 10.7759/cureus.60947.

References
1.
Schmidt J, Asper F, Einecke G, Eden G, Hafer C, Kielstein J . Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments - a one-year retrospective analysis. BMC Nephrol. 2018; 19(1):12. PMC: 5769505. DOI: 10.1186/s12882-017-0803-3. View

2.
Busund R, Koukline V, Utrobin U, Nedashkovsky E . Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med. 2002; 28(10):1434-9. DOI: 10.1007/s00134-002-1410-7. View

3.
Cohen J, Vincent J, Adhikari N, Machado F, Angus D, Calandra T . Sepsis: a roadmap for future research. Lancet Infect Dis. 2015; 15(5):581-614. DOI: 10.1016/S1473-3099(15)70112-X. View

4.
Stahl K, Wand P, Seeliger B, Wendel-Garcia P, Schmidt J, Schmidt B . Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial. Crit Care. 2022; 26(1):134. PMC: 9097091. DOI: 10.1186/s13054-022-04003-2. View

5.
Schwartz J, Winters J, Padmanabhan A, Balogun R, Delaney M, Linenberger M . Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013; 28(3):145-284. DOI: 10.1002/jca.21276. View